Real life study of three years omalizumab in patients with difficult-to-control asthma

Allergologia et Immunopathologia

Volumn 43, Issue 2, 2015, Pages 120-126

  López Tiro, J Jesús ^a   Contreras, E Angélica Contreras ^a   del Pozo, M Elena Ramírez ^a   Vera, J Gómez ^a   Linnemann, D Larenas ^b  

^a ISSSTE ^*  (Mexico)

^b Hospital Medica Sur   (Mexico)

Author keywords

Anti IgE; Asthma exacerbation; Asthmatic crisis; Biological; Difficult to control asthma; Emergency room; Hospitalisation; Omalizumab; Severe asthma

Indexed keywords

BECLOMETASONE; DEFLAZACORT; METHYLPREDNISOLONE; MONTELUKAST; OMALIZUMAB; PREDNISONE; SALMETEROL; ANTIASTHMATIC AGENT; IMMUNOGLOBULIN E;

ADOLESCENT; ADULT; AGED; ANAPHYLAXIS; ARTICLE; ASSESSMENT OF HUMANS; ASTHMA; ASTHMA CONTROL TEST; COHORT ANALYSIS; COMPARATIVE EFFECTIVENESS; CORTICOSTEROID THERAPY; DIFFICULT TO CONTROL ASTHMA; DISEASE CONTROL; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG COST; DRUG DOSE REDUCTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FORCED EXPIRATORY VOLUME; HEADACHE; HOSPITAL; HUMAN; LUNG FUNCTION TEST; LUNG TUBERCULOSIS; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; OBSERVATIONAL STUDY; PROSPECTIVE STUDY; TERTIARY CARE CENTER; DISEASE COURSE; EMERGENCY HEALTH SERVICE; IMMUNOLOGY; MEXICO; MIDDLE AGED; TIME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTI-ASTHMATIC AGENTS; ASTHMA; BECLOMETHASONE; DISEASE PROGRESSION; EMERGENCY MEDICAL SERVICES; FEMALE; HUMANS; IMMUNOGLOBULIN E; MALE; MEXICO; MIDDLE AGED; OMALIZUMAB; RESPIRATORY FUNCTION TESTS; TIME FACTORS; YOUNG ADULT;

EID: 84926245902     PISSN: 03010546     EISSN: 15781267     Source Type: Journal    
DOI: 10.1016/j.aller.2013.11.008     Document Type: Article

References (33)

1. Lotvall J., Akdis C.A., Bacharier L.B., Bjermer L., Casale T.B., Custovic A., et al. Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome. J Allergy Clin Immunol 2011, 127:355-360.
2. Neffen H. Consenso Latinoamericano sobre el Asma de dificil control, actualización 2008. Drugs Today 2008, 44:1-43.
3. Humbert M., Beasley R., Ayres J., Slavin R., Hebert J., Bousquet J., et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005, 60:309-316.
4. Godard P., Chanez P., Siraudin L., Nicoloyannis N., Duru G. Costs of asthma are correlated with severity: a 1-yr prospective study. Eur Respir J 2002, 19:61-67.
5. Becerril-Ángeles M., Pérez-Chavira R., Martínez-Aguilar N. Treatment of persistent and difficult-to-control asthma: updating of anti IgE therapy. Rev Alergia Mex 2011, 58(Suppl. 1):1-18.
6. Proceedings of the ATS workshop on refractory asthma: current understanding, recommendations, and unanswered questions American Thoracic Society. Am J Respir Crit Care Med 2000, 162:2341-2351.
7. Navarro Merino M., Martín A.A., Asensio de la Cruz O. Guía de diagnóstico y tratamiento del asma de control difícil en el niño. An Pediatr (Barc) 2009, 71:548-567.
8. Lanier B., Bridges T., Kulus M., Taylor A.F., Berhane I., Vidaurre C.F. Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma. J Allergy Clin Immunol 2009, 124:1210-1216.
9. Turner S., Paton J., Higgins B., Douglas G. British Guidelines on the Management of A. British guidelines on the management of asthma: what's new for 2011?. Thorax 2011, 66:1104-1105.
10. British Guideline on the Management of Asthma. Thorax 2008, 63(Suppl. 4):iv1-iv121.
11. Ultimo accessed 13.08.09. http://www.gemasma.com/presentacion/index.asp.
12. Hurst J.W., Morris D.C., Alexander R.W. The use of the New York Heart Association's classification of cardiovascular disease as part of the patient's complete Problem List. Clin Cardiol 1999, 22:385-390.
13. Thomas D.M., Navarro-Barrientos J.E., Rivera D.E., Heymsfield S.B., Bredlau C., Redman L.M., et al. Dynamic energy-balance model predicting gestational weight gain. Am J Clin Nutr 2012, 95:115-122.
14. Korn S., Thielen A., Seyfried S., Taube C., Kornmann O., Buhl R. Omalizumab in patients with severe persistent allergic asthma in a real-life setting in Germany. Respir Med 2009, 103:1725-1731.
15. Klyucheva M., von Berg A., Gappa M., Suerbaum C., Berdel D. Omalizumab therapy in adolescents with severe allergic asthma - results of a post-marketing surveillance. Pneumologie 2013, 67:233-237.
16. Lafeuille M.H., Dean J., Zhang J., Duh M.S., Gorsh B., Lefebvre P. Impact of omalizumab on emergency-department visits, hospitalizations, and corticosteroid use among patients with uncontrolled asthma. Ann Allergy Asthma Immunol 2012, 109:59-64.
17. To T., Shen S., Atenafu E.G., Guan J., McLimont S., Stocks B., et al. The air quality health index and asthma morbidity: a population-based study. Environ Health Perspect 2013, 121:46-52.
18. Perry T.T., Rettiganti M., Brown R.H., Nick T.G., Jones S.M. Uncontrolled asthma and factors related to morbidity in an impoverished, rural environment. Ann Allergy Asthma Immunol 2012, 108:254-259.
19. Dewey A., Dean T., Bara A., Lasserson T.J., Walters E.H. Colchicine as an oral corticosteroid sparing agent for asthma. Cochrane Database Syst Rev 2003, CD730032.
20. Dean T., Dewey A., Bara A., Lasserson T.J., Walters E.H. Chloroquine as a steroid sparing agent for asthma. Cochrane Database Syst Rev 2003, CD003275.
21. Richeldi L., Ferrara G., Fabbri L.M., Lasserson T.J., Gibson P.G. Macrolides for chronic asthma. Cochrane Database Syst Rev 2005, CD970029.
22. Evans D.J., Cullinan P., Geddes D.M. Cyclosporin as an oral corticosteroid sparing agent in stable asthma. Cochrane Database Syst Rev 2001, CD930029.
23. Evans D.J., Cullinan P., Geddes D.M. Gold as an oral corticosteroid sparing agent in stable asthma. Cochrane Database Syst Rev 2001, CD850029.
24. Davies H., Olson L., Gibson P. Methotrexate as a steroid sparing agent for asthma in adults. Cochrane Database Syst Rev 2000, CD000391.
25. Babu K.S., Davies D.E., Holgate S.T. Role of tumor necrosis factor alpha in asthma. Immunol Allergy Clin North Am 2004, 24:583-597. v-vi.
26. Rubio-Padilla M., del Rio-Navarro B.E., Segura N.H., Sienra-Monge J.J. Difficult-to-control asthma. A bibliographical review. Rev Alerg Mex 2009, 56:115-123.
27. Poole J.A., Meng J., Reff M., Spellman M.C., Rosenwasser L.J. Anti-CD23 monoclonal antibody, lumiliximab, inhibited allergen-induced responses in antigen-presenting cells and T cells from atopic subjects. J Allergy Clin Immunol 2005, 116:780-788.
28. Hart T.K., Blackburn M.N., Brigham-Burke M., Dede K., Al-Mahdi N., Zia-Amirhosseini P., et al. Preclinical efficacy and safety of pascolizumab (SB 240683): a humanized anti-interleukin-4 antibody with therapeutic potential in asthma. Clin Exp Immunol 2002, 130:93-100.
29. Velarde-Dominguez T.S., Martinez S.E.N.P., Pantoja-Alc Ntar J.M. Acute urticaria associated to omalizumab treatment in a child with asthma. Rev Alerg Mex 2012, 59:209-213.
30. Simons F.E., Ardusso L.R., Bilo M.B., Dimov V., Ebisawa M., El-Gamal Y.M., et al. 2012 Update: World Allergy Organization Guidelines for the assessment and management of anaphylaxis. Curr Opin Allergy Clin Immunol 2012, 12:389-399.
31. Shankar T., Petrov A.A. Omalizumab and hypersensitivity reactions. Curr Opin Allergy Clin Immunol 2013, 13:19-24.
32. Shitrit D., Talker O., Metabichek A., Yaakovi I. Omalizumab treatment in patients with asthma: summary of Meir Medical Center experience with 47 patients. Harefuah 2012, 151:216-219. 54, 53.
33. Nopp A., Johansson S.G., Adedoyin J., Ankerst J., Palmqvist M., Oman H. After 6 years with Xolair; a 3-year withdrawal follow-up. Allergy 2010, 65:56-60.